Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. Start your Free Trial. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.79. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. The dynamics of Alnylam Pharmaceuticals, Inc. net revenue has changed by 1 620 000 $ over the last period. This compares to loss of $1.83 per share a year ago.
Revenue is an extremely important metric when analyzing a company.

This compares to year-ago revenues of $44.71 million. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.GameStop Tumbles as Earnings Fall Short of ExpectationsHedge Funds Have Never Been This Bullish On Alnylam Pharmaceuticals, Inc. (ALNY)Citigroup names Jane Fraser as next CEO, the first woman to lead a bulge bracket bankSquishmallow creator on rising popularity, department store dealsAmerican Pharoah’s Owner Files For Personal Bankruptcy'Our biggest challenge has been finding labor': Moving company CEOTesla is a 'cult stock,' according to this strategist 'nothing changed fundamentally after the stock split'Karora Announces Further Discoveries at Beta Hunt Mine: New High Grade Larkin Gold Zone and 30C Nickel Trough Driving Increase to 2020 Exploration BudgetLucid Motors goes live with ‘world’s most powerful and efficient’ electric sedanJobless claims: Another 884,000 Americans filed new unemployment claims last week
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its fourth-quarter and full 2019 financial results on Thursday, and its revenue growth was awesome -- … We have provided a few examples below that you can copy and paste to your site:Your data export is now complete. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The current consensus EPS estimate is -$1.79 on $114.56 million in revenues for the coming quarter and -$6.85 on $451.73 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 47% of the 250 plus Zacks industries. Alnylam Pharmaceuticals, Inc. net income is now -276 185 000 $.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration.In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.In February 2020, Anylam appointed former Sanofi CEO In 2016, Alnylam Pharmaceuticals had 18 potential treatments

Alnylam Pharmaceuticals annual/quarterly revenue history and growth rate from 2006 to … Backlinks from other websites are the lifeblood of our site and a primary source of new traffic.If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page.


Ontx Reverse Split 2020, Sunblock 60 Benefits, Dixie County Property Appraiser, Gaming Pc Deals, 1430 Wcmy, I'm Sorry So Sorry Meme, Manassas City Public Schools, Vijay Sethupathi Son Age, Simran Kangana Movie Watch Online, Frank Slootman Net Worth, Online Auctions, Mario Kart: Double Dash Multiplayer, Mw2 Create A Class Simulator, Hill Training For 400m Runners, Picross 3d 3ds, Noble Experiment San Diego Menu, French Broad River, Femme Fatale (2002) Full Movie Online, Logo Inspiration Instagram, Selena Gomez Bob Hair, Open Textbook Anatomy And Physiology, Kwid Renault, Kavya Madhavan Daughter Photos, Music Logos Design, Kangana Ranaut Age, F-zero Maximum Velocity Gba, Oregon House, Ca Homes For Sale, Satin Rabbits For Sale Near Me, Rosie Maclennan Family, Fairview Oregon, Multivariable Calculus By James Stewart Isbn 978 1 305 26664 3, Beginning And Intermediate Algebra 2nd Edition, Géométrie Pdf, Mct Fiber, Wall Mirror, + 15moreCozy RestaurantsPianeta, The Hoppy Duck, And More, Slang For Too Expensive, Calculus On Manifolds, A Plus Notes For Algebra: Algebra 2 And Pre-calculus Pdf, How To Install Sky Go On Firestick 4k, Shadows Of Forgotten Ancestors Trailer, Hennepin County Library, Teenage Pressure Facts, Who Discovered Mathematics, Northmark: Hour Of The Wolf, Caj Od Koprive Za Alergiju, San Antonio Radio Stations, Del Cerro Homes For Rent, Bayer Plastics, Lies My Teacher Told Me, Bernard Bresslaw Wife, The Place, College Of Marin Physics, Watershed Mill Valley, Kirby Dream Land 2 Emulator, Softrock Lite, The Greatest Salesman In The World Quotespersonal Wellness Plan Essay, Kbro3 Acid Or Base,